

- Group II: Claims 1-7, 9 and 11-16, drawn to a recipient mouse comprising a disruption in both alleles of a gene such that lymphocyte maturation does not occur, and exogenous transgenes that encode cytokines, and a method of making a mouse lacking in mature T and B lymphocytes and comprising exogenous cytokines, wherein the transgenes are in an embryonic stem cell, classified in class 800, subclasses 18 and 25;
- Group III: Claims 1-7 and 10-16, drawn to a recipient mouse comprising a disruption in both alleles of a gene such that lymphocyte maturation does not occur, and exogenous transgenes that encode cytokines, and a method of making a mouse lacking in mature T and B lymphocytes and comprising exogenous cytokines, wherein the transgenes are introduced through breeding with a mouse comprising the transgenes, classified in class 800, subclasses 18 and 22; and
- Group IV: Claims 17-28, drawn to a recipient mouse comprising a disruption in both alleles of a gene such that lymphocyte maturation does not occur, and a human transgene comprising a nucleic acid sequence that encodes a MHC Class II DR3 molecule, wherein the transgene comprises naturally linked DRab and DQab alleles, and methods for making the same recipient mouse, classified in class 800, subclasses 18 and 21.

The Examiner contends that the inventions of the above Groups are distinct, each from the other. Further, the Examiner states that should Applicants elect the invention of either Groups I, II or III, a single species is to be elected for prosecution on the merits among (a) a recipient mouse comprising exogenous transgenes that encode cytokines comprising IL-7, SCF and LIF; (b) a recipient mouse comprising exogenous transgenes that encode cytokines comprising GM-CSF, M-CSF and IL-6; and (c) a recipient mouse comprising exogenous transgenes that encode cytokines comprising IL-7, SCF, LIF, GM-CSF, M-CSF and IL-6, and to which species the claims shall be restricted if no generic claim is finally held to be allowable.

In order to be fully responsive, Applicants hereby elect the invention of Group IV, claims 17-28, drawn to a recipient mouse comprising a disruption in both alleles of a gene such that lymphocyte maturation does not occur, and a human transgene comprising a nucleic acid sequence that encodes a MHC Class II DR3 molecule, wherein the transgene comprises naturally linked DRab and DQab alleles, and methods for making the same recipient mouse, classified in class 800, subclasses 18 and 21.

Applicants respectfully request that the above-made remarks be entered and made of record in the file history of the present application.

Respectfully submitted,

Date January 15, 2003

Thomas E. Friebe 29,258  
Thomas E. Friebe (Reg. No.)

By: William Thomann 40,203  
William Thomann (Reg. No.)

PENNIE & EDMONDS LLP  
1155 Avenue of the Americas  
New York, New York 10036-2711  
(212) 790-9090